贝利莫司他与芦可替尼联合治疗难治性慢性移植物抗宿主病 - Suppr | 超能文献

相似文献

1

Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.贝利莫司他与芦可替尼联合治疗难治性慢性移植物抗宿主病

Bone Marrow Transplant. 2024 Feb;59(2):282-284. doi: 10.1038/s41409-023-02165-3. Epub 2023 Dec 9.

2

ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.ANZTCT 共识立场声明：芦可替尼治疗激素难治性急性和慢性移植物抗宿主病。

Intern Med J. 2023 Dec;53(12):2319-2329. doi: 10.1111/imj.16255. Epub 2023 Nov 28.

3

Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis.芦可替尼治疗慢性移植物抗宿主病的疗效和安全性：一项回顾性分析。

Ann Hematol. 2024 Sep;103(9):3755-3764. doi: 10.1007/s00277-024-05697-w. Epub 2024 Jun 25.

4

Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib.用鲁索替尼治疗慢性移植物抗宿主病后皮肤T细胞淋巴瘤的严重复发

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e32-e34. doi: 10.1111/jdv.19408. Epub 2023 Aug 23.

5

Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.芦可替尼治疗激素耐药的儿童慢性移植物抗宿主病。

Pediatr Dermatol. 2022 May;39(3):432-433. doi: 10.1111/pde.14965. Epub 2022 Mar 2.

6

Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.芦可替尼治疗儿童急性和慢性移植物抗宿主病：系统评价和个体患者数据分析荟萃分析。

Bone Marrow Transplant. 2024 Jun;59(6):765-776. doi: 10.1038/s41409-024-02252-z. Epub 2024 Feb 24.

7

Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience.鲁索替尼附加疗法用于造血细胞移植后类固醇难治性移植物抗宿主病：单机构经验

Pediatr Neonatol. 2024 Jan;65(1):85-86. doi: 10.1016/j.pedneo.2023.10.002. Epub 2023 Nov 7.

8

A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study.一种新方法可视化慢性移植物抗宿主病（cGvHD）治疗的临床获益：应用于 REACH3 研究的应答概率（PBR）。

Bone Marrow Transplant. 2024 Jan;59(1):12-16. doi: 10.1038/s41409-023-02128-8. Epub 2023 Oct 28.

9

Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease.除鲁索替尼外治疗类固醇难治性急性移植物抗宿主病的方法

Br J Haematol. 2021 Nov;195(3):306-307. doi: 10.1111/bjh.17735. Epub 2021 Aug 16.

10

Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.芦可替尼与巴利昔单抗治疗激素耐药性急性移植物抗宿主病：一项回顾性研究。

Ann Hematol. 2023 Oct;102(10):2865-2877. doi: 10.1007/s00277-023-05361-9. Epub 2023 Jul 20.

引用本文的文献

1

Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease.移植物抗宿主病临床管理中的现代挑战

Adv Exp Med Biol. 2025;1475:103-128. doi: 10.1007/978-3-031-84988-6_6.

2

Treatment Response in Individual Organs Affected by Chronic Graft-Versus-Host Disease.慢性移植物抗宿主病累及的各个器官的治疗反应

Cells. 2025 Feb 7;14(4):238. doi: 10.3390/cells14040238.

3

Chronic Graft-versus-host Disease, Part 2: Clinical Success and Roadmap to the Future.慢性移植物抗宿主病，第2部分：临床成功与未来路线图。

本文引用的文献

1

Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.近期 FDA 批准的移植物抗宿主病治疗药物

Oncologist. 2022 Aug 5;27(8):685-693. doi: 10.1093/oncolo/oyac076.

2

Three US Food and Drug Administration-approved therapies for chronic GVHD.三种美国食品和药物管理局批准的慢性移植物抗宿主病治疗方法。

Blood. 2022 Mar 17;139(11):1642-1645. doi: 10.1182/blood.2021014448.

3

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.贝罗莫苏德利治疗 2 线及以上治疗后的慢性移植物抗宿主病：ROCKstar 研究。